Our research teams are motivated by discovery and results to improve health, extend life, and enhance quality of life. We achieve this by helping our federal and academic clients run clinical trials and epidemiologic studies, while also guiding them through complex FDA regulations and submissions to get new products and devices approved, and clinical standard manuscripts published.
Rho supports studies that seek new treatments for diseases that affect the immune system. Our research teams aid the search for safer and more effective medical countermeasures, including pandemic influenza vaccinations for adults and anthrax vaccinations for our most vulnerable populations.
We support pioneering research that involves decentralized or virtual clinical trials, organ and stem cell transplantation, explores effective options for treating dental and craniofacial pain, and evaluates interventions to reduce the devastating effects of food allergies and asthma on children.
Federal Research Experience
- 20+ major prime awards over the last 25 years
- 20+ subcontract awards over the last 15 years
- 430+ total studies
- 220+ clinical trials
- Phase I-IV clinical trials, observational studies, and mechanistic studies
- Expertise engaging with 6 NIH institutes, HS/ASPR/BARDA, and the USDA
- 300+ peer-reviewed articles published in more than 96 journals, including The Lancet, Nature, and The New England Journal of Medicine
Why Choose Rho
- Low-risk, stable small business
- Rapid and agile study conduct
- Long-term federal contractor
- Expert clinical research collaborator
- End-to-end services with flexible packaging
- Decentralized or virtual clinical trial experience
Let us help guide you through complex FDA regulations and submissions to get new products and devices approved so that together, we may improve health, extend life, and enhance quality of life. We proudly invite you to experience Rho.
Rho’s clinical research experts are some of the most respected and well published in the pharmaceutical, biotech, and medical device clinical research industry. Our researchers have been published in hundreds of peer-reviewed journals, including The New England Journal of Medicine, The Lancet, Nature, Science, and other prestigious journals.
Current Federal Awards
BARDA Medical Countermeasures Clinical Studies Network (MCM CSN)
As part of the BARDA MCM CSN ID/IQ multiple award task order contract pool, Rho competes for full-service task orders to design and conduct clinical studies needed to develop medical countermeasures—drugs, vaccines, and diagnostic tests—that help protect public health against bioterrorism, pandemic influenza, and other health emergencies.
GSA One Acquisition Solution for Integrated Services (OASIS) Small Business (SB) – Pool 4
Rho is a GSA OASIS Small Business professional services contract holder in Pool 4 for Research and Development in Nanotechnology; Biotechnology; and Physical, Engineering, and Life Sciences.
NIH’s Environmental Influences on Child Health Outcomes (ECHO) Children’s Respiratory and Environment Workgroup (CREW)
The CREW is a consortium of 12 birth cohorts comprising 6,000+ research participants established to examine early-life risk factors for asthma and allergic disease. Rho’s role is to collaborate closely with the University of Wisconsin-Madison leaders of the CREW consortium to act as the coordinating center for the project, assisting with administrative coordination and study process standardization.
NIH/NIAID/DAIT Statistical and Clinical Coordinating Center (DAIT SACCC)
As the DAIT SACCC, Rho is at the forefront of providing robust, full-service support critical to the design, development, execution, monitoring, and analysis of clinical research studies sponsored by DAIT. Rho supports 9 consortia that comprise 3 disease area groups: Asthma & Allergic Diseases, Autoimmune Diseases, and Transplantation.
NIH/NIDCR Clinical Research Operations and Management Support (NIDCR CROMS)
Through the CROMS contract, Rho provides full-service and tailored clinical research support services to clinical studies on oral, dental, and craniofacial diseases that are supported by the NIDCR’s Intramural and Extramural programs.
NIH/NINDS Regulatory Affairs Consultant Services (NINDS RACS)
Rho serves as the Regulatory Affairs Consultant Services contractor for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biotechnology Products and Biologics (CREATE Bio) program.
Past Federal Awards
Over the past 20+ years, Rho has supported more than $500 million of federally-funded research across multiple federal agencies and multiple therapeutic areas. Please see below for a list of past federal awards.
Clinical Research and Operations Management Support (CROMS); NIH/NIDCR; HHSN268201400073C: 9/30/2014 – 9/29/2019; HHSN268200800017C: 9/30/2008 – 9/29/2014
Statistical and Clinical Coordinating Center for the Inner-City Asthma Consortium (ICAC): Immunologic Approaches to Reduce Asthma; NIH/NIAID; HHSN272201000052I: 9/30/2010 – 9/29/2015; N01-AI-25482: 9/30/2002 – 9/30/2011
Atopic Dermatitis Research Network: Statistical and Clinical Coordinating Center (ADRN SACCC); NIH/NIAID; HHSN272200800029C: 6/30/2010 – 7/31/2015; Atopic Dermatitis and Vaccinia Immunization Network Statistical and Data Coordinating Center (ADVN-SDCC); HHSN272200800029C: 5/17/2004 – 12/31/2011
Coordinating Center for Organ Transplant Clinical Trials; NIH/NIAID; U01AI088635: 2/5/2010 – 5/6/2015
Statistical & Clinical Coordinating Center for Autoimmune Disease Clinical Trials (SACCC- ADCT); NIH/NIAID; HHSN272200900057C: 9/30/2009 – 5/31/2015; N01-AI-25481: 9/16/2002 – 9/29/2009
Statistical and Data Coordinating Center: NIAID Immune Tolerance Network and Asthma and Allergic Diseases Cooperative Research Centers (SDCC-ITN); NIH/NIAID; HHSN272200800029C; 6/16/2008 –6/15/2015
Statistics and Data Management Center-Basic and Translational Research Program (BTRP); NIH/NHLBI; U54HL070587: 6/3/2008 – 3/31/2012
Phase II/III Trial of Sildenafil for Sickle Cell Disease Associated Pulmonary Hypertension – Data Coordinating Center (walk-PHaSST-DCC); NIH/NHLBI; HHSN26820061782C: 9/30/2006 – 6/30/2010
Stroke With Transfusions Changing to Hydroxyurea: Data Coordinating Center (SWiTCH DCC); NIH/NHLBI; U01HL078987: 8/1/2005 – 7/31/2011
Hemophilia Growth and Development Study: Pathogenesis of HIV and HCV in Hemophilia; NIH/NICHD; R01 HD41224; subaward from Children’s Hospital of Los Angeles: 9/25/2004 – 8/31/2007
Atopic Dermatitis and Vaccinia Immunization Network Statistical and Data Coordinating Center (ADVN-SDCC); NIH/NIAID; HHSN272200800029C: 5/17/2004 – 12/31/2011
Statistics and Data Management Center for the Comprehensive Sickle Cell Centers (CSCC); U54 HL070587; NIH/NHLBI; 7/1/2003 – 5/31/2008
Bacteriology and Mycology Biostatistics and Operations Unit (BAMBU); NIH/NIAID; N01-AI-15441: 5/1/2001 – 12/31/2008
Data Coordinating Center (DCC) for the National Cooperative Inner-City Asthma Study (NCICAS); NIH/NIAID; U01 AI039776: 9/1/1996 – 7/31/2006
Our passion for science makes us leaders in federally funded research
Rho Principal Investigators (PIs) must balance being leaders, researchers, authors, communicators, problem solvers, and mentors. It’s these characteristics, along with our long history of research excellence, that make it possible for our partners in federally funded projects to trust that we will assist and guide them in their research endeavors.
Peter Schmidt, Ph.D.
Chief Scientific Officer
Lynette Keyes-Elstein, Dr.P.H.
Principal Statistical Scientist
Gloria David, Ph.D.
Principal Research Scientist
Nancy Yovetich, Ph.D.
Principal Research Scientist
Bill Barry, Ph.D.
Principal Statistical Research Scientist
Cindy Visness, Ph.D.
Principal Research Scientist
- NIH: NIAID, NIDCR, NINDS, NHLBI, NIEHS, NICHD
- HHS/ASPR: BARDA
- USDA: NIFA
Federal Contracting Information
DUNS Number: 362726007
CAGE Code: 8A1W7
- 541715 (small business)
- 541714 (small business)
- 541713 (small business)
In accordance with federal regulations governing contractors who receive research funding from the Public Health Service, Rho maintains a financial conflict of interest (FCOI) policy for individuals employed or retained by Rho who participate in such research. Rho’s FCOI policy is available by clicking this link.